Lack of toxicity with long term isavuconazole use in patients with hematologic malignancy.

Related Articles

Lack of toxicity with long term isavuconazole use in patients with hematologic malignancy.

Clin Infect Dis. 2019 Mar 07;:

Authors: Dippo AJ, Kontoyiannis DP

Abstract
Prolonged courses of isavuconazole (ISA) are increasingly utilized in immunocompromised patients. Toxicities have been reported with long term use of the other triazoles. We report the first real-life tolerability data in 50 patients with hematologic malignancy receiving > 6 months of ISA. ISA was well-tolerated in our ill patient population.

PMID: 30861066 [PubMed - as supplied by publisher]